The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

Abstract

Insufficient outcomes amongst adults with major depressive disorder (MDD) provide the impetus to identify and refine therapeutic targets that are most critical to outcome from patient, provider, and societal perspectives. Towards this aim, a pivotal shift towards the transnosological domain, cognition, is occurring in the study of MDD and other brain disorders. This paper aims to provide a framework for conceptualizing and prioritizing cognitive function amongst adults with MDD with a particular view to provide a conceptual framework for research and clinical priorities. We also summarize extant data pertaining to psychotropic effects, notably antidepressants, on the cognitive dimension/domain. This narrative review was based on articles identified through a PubMed/MEDLINE search of all English-language articles published between January 1966 and October 2014. The search words were major depressive disorder, depression, unipolar depression, cognition, cognitive dysfunction, cognitive deficit, and cognitive function. The search was supplemented with a manual review of relevant references. The selection of articles for inclusion in this review was based on overall methodological quality as well as on their pertinence to informing the framework described herein. Cognitive dysfunction in MDD is a discrete domain subserved by discrete yet overlapping substrates. There is a need to provide a glossary of terms commonly employed in the cognition literature for consensus as to the appropriate screening, measurement, and monitoring tools. The guiding principle of measurement-based care should include systematic assessment and measurement of cognition in subpopulations with MDD, as a tactic to improve outcome. Relatively few treatment strategies have demonstrated efficacy specifically for the cognitive domain in MDD. The antidepressant vortioxetine has replicated evidence of specific pro-cognitive effects in adults with MDD across multiple subdomains of cognitive function. Vortioxetine is a novel antidepressant that is hypothesized to act through a combination of direct effects on receptor activity and serotonin receptor inhibition, as well as other systems. Pro-cognitive effects for other US FDA-approved agents are suggested, but pseudospecificity has not been excluded as a possible explanation of their beneficial effects on cognitive function. A disparate assortment of other agents are currently under investigation for possible benefit in mitigating cognitive deficits and improving cognitive performance (e.g., intranasal insulin, erythropoietin, anti-inflammatory agents). Non-pharmacological approaches including, but not limited to, cognitive remediation (CR), aerobic exercise, and neuromodulation are promising.

Cognitive outcome after ventral capsule/ventral striatum stimulation for treatment-resistant major depression

“…Although cognitive and mood symptoms are common in depression, there is a considerable amount of variance that is not shared which might explain these results 8 14…”

Depressive disorders: Processes leading to neurogeneration and potential novel treatments

“…stimulants, anti-inflammatory agents, antioxidants, are currently being explored as strategies for treatment. Behavioural approaches are aerobic exercise as well as cognitive remediation therapy which are also currently being evaluated (McIntyre et al, 2015b).…”

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials

“…Domains of cognition can be independently evaluated in patients with MDD using objective and self-reported measures, which provide quantitative assessment of pre-treatment cognitive function as well as change in cognitive function with treatment. Whether an antidepressant exerts an independent and clinically relevant effect on cognitive function that is not mediated through improvement in other depressive symptoms has both conceptual and clinical implications, and several methodological aspects of clinical trial design are crucial in order to determine that an antidepressant has direct effects on cognitive dysfunction (McIntyre et al, 2015a). Trials should pre-specify cognition as the primary dependent measure, include a placebo arm and an active reference, and employ a statistical approach (e.g.…”